The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP)

References

1. 1.↵
   U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry—Container Closure Systems for Packaging Human Drugs and Biologics, 1999.
2. 2.↵
   U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft Guidance for Industry—Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products, 1998.
3. 3.↵
   U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry—Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation, 2002.
4. 4.↵
   European Medicines Agency, Committee for Medicinal Products for Human and Use (CHMP) and Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on Plastic Immediate Packaging Materials, 2005.
5. 5.↵
   Product Quality Research Institute (PQRI), Leachables and Extractables Working Group. Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products; Product Quality Research Institute: Arlington, VA, 2006.
6. 6.↵
   1. Ball D.,
   2. Paskiet D.,
   3. Norwood D. L.,
   4. Jenke D.

   PQRI Research Project Proposal: Reporting and Qualification Thresholds in Parenteral and Ophthalmic Drug Products; Product Quality Research Institute: Arlington, VA March 2007; available at http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/Addl/PQRI_PODP_proposal_04072.pdf.
7. 7.↵
   PQRI. Parenteral and Ophthalmic Drug Products (PODP) Work Plan; Product Quality Research Institute: Arlington, VA, 2008; available at http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/Addl/podp_work_plan_schedule.pdf.
8. 8.↵
   Study Protocol—Stage 1 Experimental Protocol for Qualitative Controlled Extraction Studies for Material Test Articles Representative of Prefilled Syringe (PFS) and Small Volume Parenteral (SVP) Container Closure Systems, Amendment #1; Product Quality Research Institute: Arlington, VA, September 2011; available at http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/Addl/StudyProtocolStage1amend1.pdf.
9. 9.↵
   U.S. Department of Health and Human Services, Food and Drug Administration, Pharmaceutical Quality for the 21^st Century A Risk-based Approach. 2009; available at http://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/questionsandanswersoncurrentgoodmanufacturingpracticescgmpfordrugs/ucm071836.
10. 10.↵
    1. Jenke D.

    Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. PDA J. Pharm. Sci. Technol. 2002, 56 (6), 332–371.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Jenke D.

    Extractable substances from plastic materials used in solution contact applications: an updated review. PDA J. Pharm. Sci. Technol. 2006, 60 (3), 191–207.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Jenke D.

    Compatibility of Pharmaceutical Products and Contact Materials; John Wiley & Sons, Inc.: Hoboken, New Jersey, 2009.
13. 13.
    1. Jenke D.

    A general strategy for the chemical aspects of the safety assessment of extractables and leachables in pharmaceutical drug products: the chemical assessment triad. PDA J. Pharm. Sci. Technol. 2012, 66 (2), 168–183.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    International Atomic Energy Agency. Controlling Degradation Effects in Radiation of Processing Polymers, IAEA-TECDOC 1611, Vienna, Austria, 2009, ISSN 1011–4289.
15. 15.↵
    1. Curry W.,
    2. Conway S.,
    3. Goodfield C.,
    4. Miller K.,
    5. Mueller R. L.,
    6. Polini E.

    Reducing the risk of contamination of sterile parenteral products using ready-to-use components. AAPS PharmSciTech 2010, 11 (4) 1572–1579.

    OpenUrlPubMed
16. 16.↵
    1. Petersen M. C.,
    2. Vine J.,
    3. Ashley J. J.,
    4. Nation R. L.

    Leaching if 2-(2-hydroeyethylmercapto) benzothiazole into contents of disposable syringes. J. Pharm. Sci. 1981, 70 (10), 1139–1143.

    OpenUrlPubMed
17. 17.↵
    1. Reepmeyer J. C.,
    2. Juhl Y. H.

    Contamination of injectable solutions with 2-mercaptobenzothiazole leached from rubber closures. J. Pharm. Sci. 1983, 72 (11), 1302–1305.

    OpenUrlPubMed
18. 18.↵
    1. Jaehnke R. W. O.,
    2. Joerg R. G.

    Interaction of rubber closures with powders for parenteral administration. J. Paren. Sci. Technol. 1990, 44 (5), 282–288.

    OpenUrl
19. 19.↵
    1. Jaehnke R. W. O.,
    2. Linde H.,
    3. Mosandl A.,
    4. Kreuter J.

    Contamination of injectable powders by volatile hydrocarbons from rubber stoppers. The C-13-oligomer and determination of its structure. Acta Pharm. Technol. 1990, 36 (3), 139–148.

    OpenUrl
20. 20.↵
    1. Danielson J. W.

    Toxicity potential of compounds found in parenteral solutions with rubber stoppers. J. Paren. Sci. Technol. 1992, 46 (2), 43–47.

    OpenUrl
21. 21.↵
    1. Bergendorff O.,
    2. Persson C.,
    3. Luedtke A.,
    4. Hansson C.

    Chemical changes in rubber allergens during vulcanization. Contact Dermatitis 2007, 57 (3), 152–157.

    OpenUrlPubMed
22. 22.↵
    1. Sharma B.,
    2. Bader F.,
    3. Templeman T.,
    4. Lisi P.,
    5. Ryan M.,
    6. Heavner G. A.

    Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX®. Eur. J. Hosp. Pharm. 2004, 5, 86–91.

    OpenUrl
23. 23.↵
    1. Pang J.,
    2. Blanc T.,
    3. Brown J.,
    4. Labrenz S.,
    5. Villalobos A.,
    6. Depaolis A.,
    7. Gunturi S.,
    8. Grossman S.,
    9. Lisi P.,
    10. Heavner G. A.

    Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation–component interface. PDA J. Pharm. Sci. Technol. 2007, 61 (6), 423–432.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Driver W. E.

    Plastics Chemistry and Technology; Van Nostrand Reinhold Co.: New York, 1979.
25. 25.↵
    1. Ulsaker G. A.,
    2. Korsnes R. M.

    Determination of cyclohexanone in intravenous solutions stored in PVC bags by gas chromatography. Analyst 1977, 102 (1220), 882–883.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Arbin A.,
    2. Ostelius J.,
    3. Callmer K.,
    4. Sroka J.,
    5. Hanninen K.,
    6. Axelsson A.

    Migration of chemicals from soft PVC bags into intravenous solutions. Acta Pharm. Seuc. 1983, 3, 20–33.

    OpenUrl
27. 27.↵
    1. Srivastava S. P.,
    2. Saxena A. K.,
    3. Seth P. K.

    Migration of di-(2-ethylhexyl) phthalate (DEHP) from plastic containers used for packaging of infusion solutions. Indian J. Pharm Sci. 1985, July/August, 156–158.
28. 28.↵
    1. Snell R. P.

    ; Capillary GC analysis of compounds leached into parenteral solutions packaged in plastic bags. J. Chromatogr. Sci. 1989, 27 (9), 524–528.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Ulsaker G. A.,
    2. Teien G.

    Identification of caprolactam as a potential contaminant in parenteral solutions stored in overwrapped PVC bags. J. Pharm. Biomed. Anal. 1992, 10 (1), 77–80.

    OpenUrlPubMed
30. 30.↵
    1. Snell R. P.

    Solid-phase extraction and liquid chromatographic determination of monophthalates and phthalide extracted from solution administration sets. J. AOAC Int. 1993, 76 (3), 531–534.

    OpenUrlPubMed
31. 31.↵
    1. Pearson S. D.,
    2. Trissel L. A.

    Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am. J. Health-Syst. Pharm. 1993, 50 (7), 1405–1409

    OpenUrlAbstract
32. 32.↵
    1. Hill S. S.,
    2. Shaw B. R.,
    3. Wu A. H. B.

    Plasticizers, antioxidants, and other contaminants found in air delivered by PVC tubing used in respiratory therapy. Biomed. Chromatogr. 2003, 17 (4), 250–262.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Nakamura Y.,
    2. Nakazawa K.,
    3. Ohmori S.,
    4. Kawano K.,
    5. Shin'ichirou N.,
    6. Kitada M.

    Investigation of the involvement of a surfactant in the leaching of diethylhexyl phthalate from administration sets. Jpn. J. Pharm. Health Care Sci. 2004, 30 (3), 180–184.

    OpenUrl
34. 34.↵
    The National Toxicology Annual Report, 2011, The Phthalate Initiative, NIH 12-5971, http://ntp.niehs.nih.gov/ntp/Pubs/NTP2011_AnnualReport_508.pdf#search=dehp.
35. 35.↵
    1. Seymour R. B.,
    2. Cheng T.

    Advances in Polyolefins: The World's Most Widely Used Polymers; University of California; Plenum Press, 1987.
36. 36.↵
    1. Nollet L. M. L.

    Handbook of Food Analysis, 2nd ed.; Marcel Dekker: New York, 2004.
37. 37.↵
    1. Jenke D. R.,
    2. Zietlow D.,
    3. Garber M. J.,
    4. Sadain S.,
    5. Reiber D.,
    6. Terbush W.

    Accumulation of extractables in buffer solutions from a polyolefin plastic container. PDA J. Pharm. Sci. Technol. 2007, 61 (4), 286–302.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Chang J. Y.,
    2. Xiao N. J.,
    3. Zhu M.,
    4. Zhang J.,
    5. Hoff E.,
    6. Russell S. J.,
    7. Katta V,
    8. Shire S. J.

    Leachables from saline-containing IV bags can alter therapeutic protein properties. Pharm. Res. 2010, 27 (11), 2402–2413.

    OpenUrlPubMed
39. 39.↵
    1. Klapperich C.,
    2. Pruitt L.,
    3. Komvopoulos K.

    Chemical and biological characteristics of low-temperature plasma treated ultra-high molecular weight polyethylene for biomedical applications. J. Mater. Sci. Mater. Med. 2001, 12 (6), 549–556.

    OpenUrlPubMed
40. 40.↵
    1. Jakobs A.

    Topas cyclic-olefin copolymer—advances in pharma packaging and pre-fillable drug delivery systems. In Medical Polymers 2000—14th International Conference, Vienna, Austria, September, 2000.
41. 41.↵
    1. Grimm M.

    Cyclic olefin copolymer (COC): an innovative transparent plastic material for applications in medical and diagnostic. In Medical Polymers 2006—5th International Conference Focusing on Polymers used in the Medical Industry; Cologne, Germany, June, 2006.
42. 42.↵
    U.S. Food and Drug Administration. Response to Petition on Bisphenol A (BPA). Available at http://www.fda.gov/Food/FoodborneIllnessContaminants/ChemicalContaminants/ucm166145.htm
43. 43.↵
    1. Haishima Y.,
    2. Hayashi Y.,
    3. Yagami T.,
    4. Nakamura A.

    Elution of bisphenol-A from hemodialyzers of polycarbonate and polysulfone resins. J. Biomed. Res. 2001, 58 (2), 209–215.

    OpenUrl
44. 44.↵
    1. Pan F.,
    2. Harmon K.,
    3. Toscano F.,
    4. Liu R.,
    5. Vivilecchia A.

    Strategy for identification of leachables in packaged pharmaceutical liquid formulations J. Pharm. Biomed. Anal. 2008, 46 (3), 520–527.

    OpenUrlPubMed
45. 45.↵
    Study Phase 2 Experimental Protocol for Simulation Study of Blow-Fill-Seal (PFS), PODP Container Closure Systems, September 2011, http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/Addl/StudyProtocolStage2.pdf.
46. 46.↵
    Product Quality Research Institute (PQRI) PODP Working Group. PQRI Workshop on Safety Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products; and Poster Exhibit, Bethesda, MD, February 22–23, 2011; http://www.pqri.org/workshops/PODP11/pdfs/Agenda_final_program.pdf.
47. 47.↵
    1. Munro I. C.,
    2. Ford R. A.,
    3. Kennepohl E.,
    4. Sprenger J. G.,
    5. Maier A.,
    6. Dourson M.

    Correlation of structural class with no-observed effect levels: A proposal for establishing a threshold of concern. Food Chem. Toxicol. 1996, 34 (9), 829–867.

    OpenUrlCrossRefPubMedWeb of Science
48. 48.↵
    1. Kroes R.,
    2. Renwick A.,
    3. Cheeseman M.,
    4. Kleiner J.,
    5. Mangelsdorf I.,
    6. Piersma A.,
    7. Schilter B.,
    8. Schlatter J.,
    9. van Schothorst F.,
    10. Vos J.,
    11. Würtzen G.

    Structure-based threshold of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food. Chem. Toxicol. 2004, 42 (1), 65–83.

    OpenUrlCrossRefPubMedWeb of Science
49. 49.↵
    ToxTree. Toxic Hazard Estimation by Decision Tree Approach; http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/qsar_tools/toxtre.
50. 50.↵
    1. Cramer G. M.,
    2. Ford R. A.,
    3. Hall R. L.

    Estimation of toxic hazard—a decision tree approach. Food Cosmet. Toxicol. 1978, 16 3, 255–276.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    Deductive Estimation of Risk from Existing Knowledge (DEREK); https://www.lhasalimited.org/derek_nexus
52. 52.↵
    1. Ball D. J.

    Establishing Threshold Levels of Extractables & Leachables in Pre-Filled Syringes. Second World Pre-Filled Syringe Summit, September 19–20, 2012, Washington, DC.
53. 53.↵
    1. Ng L.

    ; FDA Office of New Drug Quality Assessment. Current Regulatory Recommendations for Leachables in Ophthalmic Products. Presented at PQRI Workshop on Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products, Bethesda, MD, February 22–23, 2011.
54. 54.↵
    International Conference on Harmonization (ICH) M7; Assessment and Control of DNA (Mutagenic) Reactive Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, February 2013; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_Step_2.pdf.
55. 55.↵
    1. Markovic I.

    Challenges associated with extractables and/or leachable substances in therapeutic biological protein products. Am. Pharm. Rev. 2006, 9 (6), 20.

    OpenUrl
56. 56.↵
    1. Markovic I.

    Evaluation of safety and quality impact of extractable and leachable substances in therapeutic biologic protein products; a risk-based perspective. Am. Pharm. Rev. 2007, 6 (5), 487–491.

    OpenUrl
57. 57.↵
    1. Markovic I.

    Risk management strategies for safety qualification of extractables and leachable substances in therapeutic biological protein products. Am. Pharm. Rev. 2009, 12 (4), 96.

    OpenUrl
58. 58.↵
    1. Marth E.,
    2. Jelovcan S.,
    3. Kleinhappl B.,
    4. Guschi A.,
    5. Barth S.

    The effect of heavy metals on the immune system at low concentrations, International Journal of Occupational Medicine and Environmental Health. 2001, 14, 375–386.

    OpenUrlPubMed
59. 59.↵
    1. Yano K.,
    2. Ohno S.,
    3. Nakajima Y.,
    4. Toyoshima S.,
    5. Nakajin S.

    Effects of Various Chemicals Including Endocrine Disruptors and Analogs on the Secretion of Th1 and Th2 Cytokines from Anti CD3-Stimulated Mouse Spleen Cells, Journal of Health Science. 2003, 49, 195–204.

    OpenUrl
60. 60.↵
    1. Beck-Speier I.,
    2. Kreyling W. G.,
    3. Maier K. L.,
    4. Dayal N.,
    5. Schladweiler M. C.,
    6. Mayer P.,
    7. Semmler-Behnke M.,
    8. Kodavanti U. P.

    Soluble iron modulates iron oxide particle-induced inflammatory responses via prostaglandin E₂ synthesis: In vitro and in vivo studies, Particle and Fibre Toxicology. 2009, 6, 34–46.

    OpenUrl
61. 61.↵
    1. Lovik M.,
    2. Hogseth A. K.,
    3. Gaarder P. I.,
    4. Hagemann R,
    5. Eide I.

    Diesel exhaust particles and carbon black have adjuvant activity on the local lymph node response and systemic IgE production to ovalbumin. Toxicology. 1997; 121:165–178.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    1. Nilsen A.,
    2. Hagemann R.,
    3. Eide I.

    The adjuvant activity of diesel exhaust particles and carbon black on systemic IgE production to ovalbumin in mice after intranasal instillation. Toxicology 1997; 124:225–232.72.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    1. Larsen S. T.,
    2. Lund R. M.,
    3. Nielsen G. D.,
    4. Thygesen P.,
    5. Poulsen O. M.

    Di-(2-ethylhexyl) phthalate possesses an adjuvant effect in a subcutaneous injection model with BALB/c mice. Toxicol Lett. 2001; 125(1–3):11–18.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    1. Larsen S. T.,
    2. Hansen J. S.,
    3. Thygesen P,
    4. Begtrup M.,
    5. Poulsen O. M.,
    6. et al

    . Adjuvant and immuno-suppressive effect of six monophthalates in a subcutaneous injection model with BALB/c mice. Toxicology. 2001; 169:37–351.

    OpenUrlCrossRefPubMedWeb of Science
65. 65.↵
    1. Larsen S. T.,
    2. Nielsen G. D.

    The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARalpha-independent mechanism. Toxicol Lett. 2007; 170:223–228.

    OpenUrlCrossRefPubMed
66. 66.↵
    1. Locatelli F.,
    2. Aljama P.,
    3. Barany P.,
    4. et al

    . Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant. 2004; 19:288–293.

    OpenUrlFREE Full Text
67. 67.↵
    1. Naim J. O.,
    2. Ippolito K. M.,
    3. Lanzafame R. J.,
    4. van Oss C. J.

    The effect of molecular weight and gel preparation on humoral adjuvancy of silicone oils and silicone gels. Immunol Investig. 1995; 24:537–547.

    OpenUrlPubMed
68. 68.↵
    1. Naim J. O.,
    2. Satoh M.,
    3. Buehner N. A.,
    4. Ippolito K. M.,
    5. Yoshida H.,
    6. Nusz D.,
    7. Kurtelawicz L.,
    8. Cramer S. F.,
    9. Reeves W. H.

    Induction of hypergammaglobulinemia and macrophage activation by silicone gels and oils in female A.SW mice. Clin Diagn Lab Immunol. 2000; 7:366–370.

    OpenUrlPubMed